Sera Prognostics, Inc. (NASDAQ: SERA) is engaged as a health diagnostics company, which is focused around developing treatments and solutions to aid precision pregnancy care. Shares of “The Pregnancy Company” are rallying 43% through early trading on Wednesday, February 15, 2023. Over the past three months, Sera Prognostics has seen average daily volume of 28,010 shares. However, volume of 37.62 million shares or dollar volume of around $71.85 million, has already exchanged hands through early trading.
Shares of Sera Prognostics are gaining after the company reported positive top-line data from AVERT PRETERM trial (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls). The trial was conducted at ChristianaCare in Wilmington, Delaware.
The PreTRM test and treat strategy showed statistically and clinically significant results in neonatal health outcomes and hospital admittance. Sera Prognostics was testing two co-primary outcomes: reduction of severe neonatal morbidity (neonatal death) and decreased length of neonatal hospital stay. Both of the co-primary endpoints were successfully met with the PreTRM test and treat strategy.
Developed as a method for predicting spontaneous preterm births (sPTB), the PreTRM test was validated in the Proteomic Assessment of Preterm Risk (PAPR) study. In the large study, the Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP), biomarkers were shown to predict very early preterm births of any cause, as well as neonatal length of hospital stay and neonatal deaths.
“The AVERT PRETERM TRIAL results demonstrate the generalizability of the PreTRM® test-and-treat strategy in achieving meaningful clinical results in widely diverse U.S. populations,” said Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics. “Furthermore, these important AVERT PRETERM TRIAL clinical results build on and reinforce those of past studies—including PAPR, TREETOP and PREVENT-PTB. We believe the AVERT PRETERM TRIAL findings add to the growing body of evidence for the PreTRM® Test’s clinical benefit to mothers and babies, and that these new results bode well for our ongoing, large multi-center PRIME study.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
The post Sera Prognostics (NASDAQ: SERA) Releases Positive Data from AVERT PRETERM Trial appeared first on Spotlight Growth.
